ProCE Banner Activity

Multidrug-Resistant HIV With Limited Treatment Options: No Longer an Unmet Need?

Clinical Thought
For the second time in HIV history, the development of new drugs with novel mechanisms of action and no cross-resistance with any previous antiretroviral drug will allow most highly treatment–experienced patients with resistant HIV to regain virologic suppression.

Released: October 18, 2021

Expiration: October 17, 2022

No longer available for credit.

Share

Faculty

Josep M. Llibre

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

Josep M. Llibre, MD, PhD, has disclosed that he has received funds for research support from Gilead Sciences; consulting fees from Gilead Sciences, Janssen Cilag, and ViiV; and fees for non-CME/CE services from Gilead Sciences and ViiV.